XML 32 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Mar. 21, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Registrant Name LEXEO THERAPEUTICS, INC.    
Entity Central Index Key 0001907108    
Current Fiscal Year End Date --12-31    
Entity File Number 001-41855    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 85-4012572    
Entity Address, Address Line One 345 Park Avenue South    
Entity Address, Address Line Two Floor 6    
Entity Address, City or Town New York    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10010    
City Area Code 212    
Local Phone Number 547-9879    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Title of 12(b) Security Common stock, par value $0.0001    
Trading Symbol LXEO    
Security Exchange Name NASDAQ    
Document Annual Report true    
Document Transition Report false    
Entity Common Stock, Shares Outstanding   33,196,997  
Documents Incorporated by Reference [Text Block]

Portions of the Registrant’s definitive Proxy Statement relating to the 2025 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2024.

    
Entity Public Float     $ 527.9
Auditor Name KPMG LLP    
Auditor Location New York, NY    
Auditor Firm ID 185    
Auditor Opinion [Text Block]

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Lexeo Therapeutics, Inc. (the Company) as of December 31, 2024 and 2023, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.